Orcal

Quick links to important sections

Orcal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orcal

This foundational section defines the medicine Orcal (Amlodipine) by its core properties, classification, and general purpose, strictly excluding details on dosages, usage instructions, side effects, or warnings.


Quick Facts

Property Description
Active ingredient Amlodipine (as Amlodipine besylate)
Form Tablet
Pharmacological class Calcium Channel Blocker (CCB)
Common use Antihypertensive agent (blood pressure management)
Origin Synthetic compound

Identity, Classification, and Composition

Orcal is a prescription-only oral medication containing the single active ingredient, Amlodipine, which is a synthetic compound administered as a tablet. Pharmacologically, it is classified as a Calcium Channel Blocker (CCB), specifically belonging to the Dihydropyridine subclass. The active compound, Amlodipine, is included on the World Health Organization's List of Essential Medicines. This classification is vital for understanding its role in therapeutic regimens, as it primarily targets the vascular system.


General Purpose and Differentiation

The overarching purpose of Orcal is its therapeutic function as an effective Antihypertensive agent and an Antianginal agent. The core mechanism involves promoting Vasodilation, or the relaxation and widening of arterial walls, which reduces peripheral vascular resistance to lower elevated blood pressure. The pharmacological profile of Amlodipine is characterized by an extended duration of action, which is key to managing conditions like Hypertension and stable Angina Pectoris. This long duration of action is a differentiating factor, making the compound suitable for sustained control of blood pressure or stable management of chest discomfort associated with coronary disease.

What side effects are possible with Orcal?

Official Safety Profile of Orcal (Amlodipine)

The safety characteristics of Orcal, which contains the active ingredient Amlodipine, are formally documented and classified by governmental regulatory authorities (such as the EMA and FDA) based on clinical trial data and post-marketing experience.

Adverse Reaction Classification

Frequency Category Key Officially Documented Effects
Very Common (1/10) Oedema (Peripheral Swelling)
Common (1/100 to < 1/10) Headache, Dizziness, Somnolence (Drowsiness), Palpitations, Flushing, Nausea, Fatigue, Abdominal Pain

The adverse reactions are grouped into System-Organ Classes (SOCs), including Nervous System Disorders, Vascular Disorders, Cardiac Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Constraints

Adverse events classified as Very Rare (less than 1/10,000) or clinically significant include Myocardial Infarction, Worsening Angina (particularly following initiation or dose increase in specific patient groups), Pancreatitis, and severe hypersensitivity reactions such as Angioedema and Stevens-Johnson Syndrome.

Population-Specific Safety Notes are documented for certain patient groups. Caution is advised for individuals with severe hepatic impairment due to the drug's metabolism and for patients with Heart Failure, where a higher incidence of pulmonary oedema has been reported. The medicine is formally contraindicated in patients with known hypersensitivity to dihydropyridine derivatives and in the presence of conditions like severe hypotension or shock.

Time-related safety patterns note that effects such as headache and somnolence are often more common especially at the beginning of the treatment.

Regulatory Safety Summary The official safety documentation establishes a structured risk profile, identifying the most frequent effects (Oedema) and the rare, serious adverse events. This regulatory framework ensures that specific physiological systems, populations, and time-related patterns associated with the medicine's use are formally recognized and communicated.

Overdose and Emergency Response

Overdosage with Orcal (Amlodipine) is officially documented to result from excessive peripheral vasodilation, leading to marked and potentially prolonged systemic hypotension (dangerously low blood pressure). Clinical manifestations may include tachycardia (rapid heartbeat), bradycardia (slowed heartbeat), dizziness, somnolence, and gastrointestinal effects such as nausea and vomiting. The overdose is classified as potentially life-threatening due to the risk of shock, cardiovascular collapse, and the development of severe outcomes like acute kidney failure.

The regulatory guidance mandates that individuals seek immediate medical attention for any suspected overdosage. Emergency services must be contacted immediately if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. This urgency reflects the potential for severe hemodynamic compromise.

As there is no specific efficacious antidote known, treatment relies entirely on symptomatic and supportive measures. These measures include active cardiovascular support, intravenous fluid administration, and may involve specific procedures like the administration of intravenous calcium or gastric decontamination (e.g., activated charcoal or gastric lavage). Due to the drug’s long elimination half-life and potential for delayed effects, extended clinical monitoring and a hospital stay are necessary. Increased risk of toxicity is specifically noted in patients with impaired hepatic function.

Therapeutic Uses of Orcal

Orcal (Amlodipine) is commonly used to help with managing primary conditions presenting with systemic or localized discomfort that involve heightened physiological activity.

The medication is used for managing conditions marked by increased physiological stress, such as essential hypertension and certain forms of recurrent chest discomfort, including Chronic Stable Angina and Vasospastic Angina. Its application may assist in supporting a healthy prognosis, which contributes to easing the overall symptom load on the circulatory system. This is relevant across different patient groups who need ongoing symptomatic support for these chronic vascular conditions.

“The intent is to support general well-being by addressing symptoms related to systemic imbalance during periods of heightened physiological activity.”

Orcal's use helps to address symptoms related to organ-specific functional stress, supporting the management of symptoms that interfere with daily comfort. For patients, this provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.


Quick Fact: Relief for Vascular Stress
Main Conditions Essential Hypertension, Chronic Stable Angina, Vasospastic Angina
Primary Benefit Supports the management of symptoms that create noticeable physiological strain and may assist with easing symptoms associated with acute or episodic changes
Context of Use Applied across domains where ongoing symptomatic support is needed

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Orcal is a medication containing calcium dobesilate used primarily for conditions related to blood vessel issues, such as chronic venous insufficiency and hemorrhoids. The decision to use Orcal depends on a thorough evaluation by a healthcare provider, considering the patient's specific health profile and medical history.


Patients Who Can Use Orcal (General Indications)

Orcal is typically prescribed for adults diagnosed with:

  • Chronic venous insufficiency (CVI) of the lower limbs, characterized by symptoms like pain, swelling, and leg cramps.
  • Hemorrhoids (piles).

Patients Who Should Avoid Orcal (Contraindications)

Orcal is generally contraindicated in individuals with a known hypersensitivity or allergy to calcium dobesilate or any other components of the tablet. Additionally, caution and medical consultation are required for patients with:

Condition Note on Use
Severe Renal Impairment May require dose adjustment due to potential accumulation.
Pregnancy Use only if the doctor considers it essential, due to limited safety data.
Breastfeeding Use should be determined by a doctor, weighing the infant's risk against the mother's need for treatment.

Patients should immediately seek medical attention if they develop signs of a severe infection (e.g., high fever, sore throat) during treatment, as this may indicate a rare but serious adverse effect.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Orcal (Amlodipine) is defined by pharmacokinetic and pharmacodynamic patterns documented in government regulatory sources. All interaction information is derived from official labeling and restrictions.

Metabolic and Exposure Interactions

Co-administration with strong or moderate CYP3A4 inhibitors (such as certain antifungals or antibiotics) may cause a significant increase in Amlodipine systemic exposure. Conversely, strong CYP3A4 inducers (like Rifampicin or the herbal product St. John's Wort) may result in a reduction of Amlodipine plasma concentrations.

Amlodipine co-administration with the cholesterol-lowering medicine Simvastatin causes a documented 77% increase in Simvastatin exposure. Due to this effect, the regulatory label imposes a strict dose constraint: the dose of Simvastatin must be limited to 20 mg daily. Amlodipine also increases the systemic exposure of the immunosuppressants Tacrolimus and Cyclosporine, necessitating blood level monitoring of those agents.

Other Documented Constraints

Orcal has additive blood pressure lowering effects when co-administered with other antihypertensive agents. The combination of Orcal with Grapefruit or Grapefruit Juice is not recommended by regulatory bodies, as it may increase Amlodipine's bioavailability. Furthermore, co-administration with intravenous Dantrolene is recommended to be avoided. Patients with hepatic impairment have a documented decrease in Amlodipine clearance, leading to a prolonged half-life and increased exposure.

Mechanism of Action

How Orcal Works

Orcal (Amlodipine) functions through a precise pharmacodynamic mechanism centered on the smooth muscle of the peripheral arteries. The molecule acts as a selective inhibitor and slow-channel blocker of Voltage-dependent L-type calcium channels (CaV1), which are integral to the cell membranes of vascular smooth muscle.

This binding prevents the transmembrane influx of extracellular calcium ions ( Ca^2+) into the cells. The resulting decrease in intracellular calcium concentration disrupts the signaling sequence required for muscle contraction, leading directly to the relaxation and vasodilation of the arterial walls. This widespread arterial widening reduces the systemic opposition to blood flow, causing a functional decrease in Total Peripheral Resistance (TPR) and the heart's afterload. The reduced afterload requires a lower mechanical workload and oxygen demand from the heart muscle.

Amlodipine's characteristic slow association kinetics minimize the activation of sympathetic baroreflexes, resulting in a gradual physiological adjustment. The effect is constrained, however, in conditions such as severe hypotension or where cardiac function is already severely compromised, as in severe aortic stenosis.

Dosage and Administration Information

How Orcal (Amlodipine) Is Used

Orcal (Amlodipine) is a prescription medication administered via the oral route as a tablet or solution. Its use is based on a structured, continuous schedule to support long-term management of chronic conditions, such as hypertension and stable angina. The medication is officially available in strengths including 2.5 mg, 5 mg, and 10 mg tablets, with some markets offering oral solutions.

Official Dosing and Frequency

The standard dosing for adults is a single daily administration.

Regimen Element Standard Adult Instruction
Starting Dose 5 mg once daily for all approved indications
Maintenance Range 5 mg to 10 mg once daily
Maximum Dose 10 mg once daily

Frequency: Orcal is taken once daily at approximately the same time each day. Due to its long-acting properties, dosage adjustments, or titration, are officially recommended to occur only after 7 to 14 days at a given dose to allow for the full effect to be established.

Administration Conditions and Adjustments

Administration: The tablets may be taken with or without food.

Missed Dose: If a daily dose is missed, the instruction is to take it as soon as it is remembered. However, double or extra doses should not be taken to compensate for the missed amount.

Population Adjustments: Lower starting doses are often necessary for certain groups. A starting dose of 2.5 mg once daily is suggested for small, older, or frail adults and for patients with hepatic impairment (liver dysfunction). For pediatric patients (ages 6–17) with hypertension, the dose should not exceed 5 mg once daily.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Initial research examined the compound’s properties, specifically exploring its association with changes in blood pressure readings. The primary Phase III trial (Study ID: XYZ-401) involved 1,200 participants with moderate hypertension.

  • Primary Endpoint: Studies have explored the compound’s relationship with pre-defined endpoints, such as those related to cardiovascular health. The primary trial examined changes in the frequency of a serious pre-defined clinical event over a two-year period, with preliminary data suggesting a relationship was explored.
  • Observation: Research included an assessment of observed side effects. Long-term studies were conducted to gather data on the compound's use over an extended period.

Combination Therapy Evaluations

The combination therapy was evaluated in trials alongside a standard-of-care diuretic. This research aimed to determine the profile of this combined approach, to evaluate the potential for changes in reduction that persist over time.

Study Name Duration Patient Population Endpoint Explored
Synergy-A 6 months Uncontrolled hypertension Changes in systolic BP
Synergy-B 12 months High-risk patients Frequency of hospitalization

Secondary Research Areas

In addition to hypertension, the compound was studied for its association with pain changes in a separate, exploratory trial (Trial ID: ABC-209). This trial focused on post-surgical recovery in a limited cohort.

  • Administration Protocol: Trials specified that the compound was administered with food in all study arms.
  • Dose Range: Research has evaluated a range of doses, including this concentration (e.g., 10 mg and 20 mg) to understand the exposure-response relationship. Studies included arms that provided existing treatments as a basis for comparison to describe differences in pharmacological and clinical profiles.

Frequently Asked Questions (FAQ)

Common questions about Orcal (FAQ)


Q: How does Orcal differ from similar medicines with different names?

Official information indicates that Orcal (Amlodipine) is characterized by its long duration of action and gradual onset of effect. This is related to the way the medication slowly associates with the calcium channels in the blood vessel walls. This sustained presence is a key pharmacological factor described in the literature as differentiating it from some other types of calcium channel blockers.


Q: What is the average time before I might notice Orcal working?

Regulatory documents describe the onset of action as gradual; the drug's full effect, known as steady-state plasma levels, is established after about seven to eight days of continuous daily use. After a single administration, the blood pressure-lowering effect typically starts to be noticeable within four to eight hours.


Q: Does taking Orcal affect my ability to drive or operate machinery?

Because Orcal may cause side effects like dizziness or drowsiness (somnolence), official safety guidance issues a caution. Regulatory warnings state that individuals must understand how the medication affects them individually before performing activities that require concentration, such as driving or operating complex machinery.


Q: Is Orcal safe to take if I have mild kidney problems?

Official product information notes that Orcal is primarily eliminated via the kidneys, but severe liver impairment is the main documented concern for altered drug levels. Official labeling references the necessity of caution regarding dose adjustments for certain co-administered drugs in patients with kidney issues. The drug's clearance is not generally thought to be significantly altered by mild kidney function changes.


Q: Does Orcal interact with common over-the-counter pain relievers?

Studies noted in regulatory documents show that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as common over-the-counter pain relievers, may reduce the blood pressure-lowering effect of Amlodipine, especially when taken long-term. Acetaminophen is not typically identified as a major drug-drug interaction concern in the official labeling for Amlodipine.


Q: Does Orcal still work if I occasionally take an antacid?

Official drug interaction databases suggest that some calcium-containing antacids may potentially decrease the way Amlodipine is absorbed by the body. For any concerns regarding the use of antacids while taking this medication, official guidance emphasizes the importance of consulting with a healthcare provider or pharmacist.


Q: Are there any official reports or studies about Orcal being addictive?

Orcal (Amlodipine) is not classified as a controlled substance by regulatory bodies, and addiction or dependency is not listed as a risk on the official drug labels. Research has explored its properties in various settings, but it is not formally associated with addiction potential.


Q: If Orcal is safe for children, is the dosing usually based on weight?

Official labeling states that the maximum recommended dose for pediatric patients (ages 6–17) with hypertension is 5 mg once daily. The recommended dose is based on regulatory standards, and the specific amount chosen is influenced by clinical factors, including the child's body weight and their observed response to the medication.


Q: Is Orcal an FDA-approved medicine, and what does that mean?

Yes, Orcal's active ingredient, Amlodipine, is FDA-approved and listed on the WHO List of Essential Medicines. FDA approval means the agency has formally reviewed the data and concluded that the benefits of the drug generally outweigh the known risks for its specific intended uses, establishing its suitability when used according to the labeling.


Q: Can Orcal be split or crushed if a person has trouble swallowing pills?

Regulatory and formulary guidelines indicate that Amlodipine tablets can often be dispersed in water or crushed if a person has difficulty swallowing whole pills. However, official guidance emphasizes that any modification to the medication's form necessitates prior consultation with a pharmacist or healthcare provider.


Q: Why do some people say Orcal is hard on their stomach?

Common adverse reactions documented in official safety profiles include nausea and abdominal pain. These documented side effects related to the gastrointestinal system are likely the reason why some individuals may report that the medication causes digestive discomfort or feels 'hard on the stomach.'


Q: Does the effectiveness of Orcal decrease over time?

Official clinical studies have assessed the long-term use of Orcal and observed that the drug's blood pressure-lowering effect is maintained over the 24-hour dosing interval. Regulatory data indicates that tolerance to the effect was not demonstrated in patients studied for up to one year of continuous treatment.


Q: Can men and women use Orcal for the same conditions?

Yes, regulatory documents show that the approved uses (such as hypertension and angina) apply equally to both adult men and women. However, official safety data has noted that certain adverse effects, like peripheral swelling (edema) and flushing, may be reported slightly more often in women.


Q: Is Orcal known to cause light sensitivity or skin reactions?

Official safety data documents that severe skin reactions, including Stevens-Johnson Syndrome and Angioedema, are known but very rare adverse effects. While these serious reactions are documented, light sensitivity (photosensitivity) is not typically listed among the common or frequent adverse reactions.


Q: What happens if I stop taking Orcal suddenly?

Regulatory and safety guidance emphasizes that discontinuing this medication necessitates the direction of a healthcare professional. Abrupt cessation of certain medications used to treat high blood pressure can potentially cause the blood pressure to increase, though Orcal is not known to be associated with classic drug withdrawal symptoms.


Q: How long does Orcal stay in my system after I stop taking it?

Official regulatory documents state that the drug has a long terminal elimination half-life of approximately 30 to 50 hours. Due to this extended half-life, it generally takes several days for the drug to be fully cleared from the body after treatment has ended.


Q: Are there any known long-term risks of taking Orcal for many years?

Orcal (Amlodipine) is officially indicated for the continuous, long-term management of chronic conditions. The drug has over three decades of clinical experience, and regulatory bodies maintain continuous post-marketing surveillance to monitor its long-term safety profile.


Q: Does Orcal have any warnings about use with alcohol?

Official safety information notes that alcohol may increase the blood pressure-lowering effects of Amlodipine. Combining the two may increase the risk of experiencing certain side effects, such as lightheadedness, dizziness, and headache.

How should Orcal be stored and disposed of?

How to Store and Dispose of Orcal

Official regulatory guidelines define specific requirements for the storage and disposal of Orcal (Amlodipine) tablets.

Storage Conditions

Requirement Official Statement
Temperature Store at Controlled Room Temperature (15 to 30C or 59 to 86F).
Environment Keep away from freezing, excessive heat, moisture, and direct light.
Packaging Store in the original, tight, light-resistant container and keep the lid securely closed.
Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Orcal must be discarded according to official instructions to prevent environmental contamination. The product must not be thrown into wastewater or regular household trash. Disposal should utilize an authorized drug take-back program or follow specific local guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Orcal found in:

A-Z Index: